SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is highly discussed due to recent analyst coverage underscoring its strategic importance as a premier U.S. uranium and rare earth producer, especially with its unique White Mesa Mill and efforts to establish a fully integrated domestic supply chain. The community anticipates further developments, focusing on the company's critical role in energy security, defense, and supporting the AI boom amidst market volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community members passionately debate the escalating conflict with Iran, with supporters touting Trump's decisive actions against the nation while critics express alarm over the war's instigation and its economic fallout, particularly surging oil prices.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is gaining significant attention following a bullish Citron Research report highlighting its leadership in protecting against emerging AI agent-driven cyber threats, fueling community discussion around its deeply undervalued status and potential for a rebound within the oversold cybersecurity sector.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is actively trending as discussions around Kraken gaining Federal Reserve payment access and political pressure for clearer crypto legislation highlight increasing institutional integration. Community sentiment remains sharply divided between those anticipating a significant breakout and others forecasting further declines amid broader market volatility.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating Israeli airstrikes on Iranian oil facilities spark widespread concern about global energy supply, fueling community debate over sustained oil price increases amid disruptions to the Strait of Hormuz.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is currently trending due to heightened acquisition speculation, with reports suggesting significant offers from major pharmaceutical companies like AstraZeneca and previous interest from Eli Lilly, following strong Phase 3 data for its obefazimod drug in ulcerative colitis. The community is actively discussing the potential of this unique inflammatory bowel disease treatment and the valuation of a possible takeover within a consolidating biotech market.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is rallying on strong earnings and bullish guidance, propelled by robust AI-driven semiconductor demand and increased sector capital expenditures, alongside analyst upgrades and its S&P 100 inclusion. This performance is fueling a debate among investors about the sustainability of its significant upward momentum.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending amidst discussions of substantial institutional inflows into its recently launched spot ETFs, fueled by perceived regulatory clarity, while community sentiment remains split between bullish adoption expectations and skepticism regarding its utility and supply dynamics.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending following record quarterly revenues, robust 2026 guidance, and a "Strong-Buy" upgrade, which is amplifying community excitement about Recorlev's market dominance after a competitor's Cushing's drug faced an FDA rejection, alongside the advancing multi-billion dollar potential of its XP-8121 pipeline.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Petroleo Brasileiro is trending as escalating geopolitical tensions in the Middle East drive crude oil prices higher, leading the community to anticipate a significant breakout for the stock. Investors are actively discussing its perceived undervaluation and strong production amidst ongoing conversations about its dividend policy and broader market dynamics.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sight Sciences (NASDAQ:SGHT) Price Target Cut to $11.00 by Analysts at UBS Group

UBS Group cut their price target on Sight Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a report on Friday...

Sight Sciences (NASDAQ:SGHT) Price Target Lowered to $6.50 at Citigroup

Citigroup decreased their price objective on shares of Sight Sciences from $9.10 to $6.50 and set a "neutral" rating for the company in a research note on Friday...

Sight Sciences Q4 Earnings Call Highlights

Sight Sciences (NASDAQ:SGHT) reported fourth-quarter 2025 results highlighting growth in both its interventional glaucoma and interventional dry eye segments, alongside what management described as...

Sight Sciences (SGHT) Q4 2025 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates

Sight Sciences (SGHT) delivered earnings and revenue surprises of +44.83% and +0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Sight Sciences Q4 Earnings Assessment

Sight Sciences (NASDAQ:SGHT) Issues Earnings Results, Beats Estimates By $0.09 EPS

Sight Sciences (NASDAQ:SGHT - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by...

Uncovering Potential: Sight Sciences's Earnings Preview

5 Analysts Assess Sight Sciences: What You Need To Know

Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Current Price	$3.71
Prev Close	$3.96
Open	$3.80
Dividend Yield	0.00%
50-Day Moving Average	$6.32
Beta	2.00
Avg. Volume	224,852.35
PE Ratio	-5.01

52-Week High	$9.24
52-Week Low	$2.03
Market Capitalization	$200.36M
EPS (Annual)	-$0.7369
Price to Book	3.10
Revenue Per Employee	$415,930.11

SGHT
Sight Sciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGHT News

SGHTSight Sciences Inc